CARBOPLATIN (car-bo-pla'tin) Paraplatin Classifications: antineoplastic; alkylating agent; Therapeutic: antineoplastic Prototype: Cyclophosphamide Pregnancy Category: D |
50 mg, 150 mg, 450 mg vials
Carboplatin is a platinum compound that is a chemotherapeutic agent. It produces interstrand DNA cross-linkages, thus interfering with DNA, RNA, and protein synthesis. Carboplatin is cell-cycle nonspecific (i.e., effective throughout the entire cell life cycle) it induces programmed cell death.
Full or partial activity against a variety of cancers resulting in reduction or stabilization of tumor size and useful in patients with impaired renal function, patients unable to accommodate high-volume hydration, or patients at high risk for neurotoxicity and/or ototoxicity.
Monotherapy or combination therapy for ovarian cancer.
Combination therapy for breast, cervical, colon, endometrial, head and neck, and lung cancer; leukemia, lymphoma, and melanoma.
History of severe reactions to carboplatin or other platinum compounds, severe bone marrow depression; significant bleeding; impaired renal function; pregnancy (category D), and lactation.
Use with other nephrotoxic drugs; coagulapathy; previous radiation therapy; renal impairment.
Ovarian Cancer Adult: IV 360 mg/m2 once q4wk. May be repeated when neutrophil count is at least 2000 mm3 and platelet count is at least 100,000 mm3. If neutrophil and platelet counts are lower, dose of carboplatin should be reduced by 5075% of initial dose. Alternatively, 400 mg/m2 as a 24-h infusion for 2 consecutive d can be used. Renal Impairment Clcr 4159 mL/min: dose 250 mg/m2; 1640 mL/min: dose 200 mg/m2 Hemodialysis: Initial dose not to exceed 150 mg/m2 |
Intravenous PREPARE: IV Infusion: Do not use needles or IV sets containing aluminum. Immediately before use, reconstitute with either sterile water for injection or D5W or NS as follows: 50-mg vial plus 5 mL diluent; 150-mg vial plus 15 mL diluent; 450-mg vial plus 45 mL diluent. All dilutions yield 10 mg/mL. May be further diluted to a concentration as low as 0.5 mg/mL with D5W or NS. ADMINISTER: IV Infusion: Give IV solution over 15 min or longer, depending on total amount of solution and patient tolerance. Lengthening duration of administration may decrease nausea and vomiting. INCOMPATIBILITIES Solution/additive: Sodium bicarbonate, fluorouracil, mesna. Y-site: Amphotericin B cholesteryl complex, lansoprazole.
|
Decreased calcium levels; mild increases in liver function tests; decreased levels of magnesium, potassium, and sodium.
Assessment & Drug Effects
Patient & Family Education